Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFM13 + cord blood-derived natural killer cells
- Development stage
- Phase 2
- Lead developer
- Affimed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AFM13 + cord blood-derived natural killer cells is an allogeneic cell-based immunotherapy developed by M.D. Anderson Cancer Center in collaboration with Affimed. The therapy consists of umbilical cord blood-derived natural killer (NK) cells that are activated with a cytokine cocktail (IL-12, IL-15, and IL-18), expanded using artificial antigen-presenting cells, and subsequently pre-complexed with AFM13 (acimtamig). AFM13 is a bispecific tetravalent Innate Cell Engager (ICE) that binds to CD16A on NK cells and CD30 on lymphoma cells, creating a bridge that enables the NK cells to target and destroy CD30-positive cancer cells. This approach creates CAR-like responses without the need for viral-mediated genetic modification of the cells. The therapy is primarily investigated for heavily pretreated patients with relapsed or refractory CD30-positive malignancies, including Hodgkin lymphoma and various types of non-Hodgkin lymphoma.
- Other names
- AFM13-preloaded umbilical cord blood NK cellsAFM-13-preloaded umbilical cord blood NK cellsAFM 13-preloaded umbilical cord blood NK cellsAFM13-complexed NK cellsAFM-13-complexed NK cellsAFM 13-complexed NK cellsacimtamig + NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD30 (CD30 antigen)
Beyond the preview
Go deeper on AFM13 + cord blood-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFM13 + cord blood-derived natural killer cells.